Phoenix Biotech Acquisiti... (PBAXW)
Phoenix Biotech Acquisition Statistics
Share Statistics
Phoenix Biotech Acquisition has - shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | - |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 940.12K |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -275.25 and the forward PE ratio is null. Phoenix Biotech Acquisition's PEG ratio is -1.6.
| PE Ratio | -275.25 |
| Forward PE | n/a |
| PS Ratio | 721.25 |
| Forward PS | null |
| PB Ratio | 74.45 |
| P/FCF Ratio | -168.27 |
| PEG Ratio | -1.6 |
Enterprise Valuation
Phoenix Biotech Acquisition has an Enterprise Value (EV) of 183.97M.
| EV / Sales | 721.93 |
| EV / EBITDA | -32.04 |
| EV / EBIT | -168.43 |
| EV / FCF | -168.43 |
Financial Position
The company has a current ratio of 1.38, with a Debt / Equity ratio of 0.26.
| Current Ratio | 1.38 |
| Quick Ratio | 1.38 |
| Debt / Equity | 0.26 |
| Debt / EBITDA | -0.11 |
| Debt / FCF | -0.6 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is -27.05% and Return on Invested Capital is -21.41%.
| Return on Equity | -27.05% |
| Return on Assets | -1.58% |
| Return on Invested Capital | -21.41% |
| Revenue Per Employee | $- |
| Profits Per Employee | $- |
| Employee Count | undefined |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 599.16K |
| Effective Tax Rate | -873.7% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0.04, so Phoenix Biotech Acquisition's price volatility has been higher than the market average.
| Beta | 0.04 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 0.04 |
| 200-Day Moving Average | 0.06 |
| Relative Strength Index (RSI) | 46.59 |
| Average Volume (20 Days) | - |
Income Statement
In the last 12 months, Phoenix Biotech Acquisition had revenue of 254.83K and earned -667.74K in profits. Earnings per share was -0.04.
| Revenue | 254.83K |
| Gross Profit | 254.83K |
| Operating Income | -68.58K |
| Net Income | -667.74K |
| EBITDA | -5.74M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.04 |
Balance Sheet
The company has 475.87K in cash and 650K in debt, giving a net cash position of -174.13K.
| Cash & Cash Equivalents | 475.87K |
| Total Debt | 650K |
| Net Cash | -174.13K |
| Retained Earnings | -10.76M |
| Total Assets | 8.47M |
| Working Capital | 3.67M |
Cash Flow
In the last 12 months, operating cash flow was -1.09M and capital expenditures 0, giving a free cash flow of -1.09M.
| Operating Cash Flow | -1.09M |
| Capital Expenditures | 0 |
| Free Cash Flow | -1.09M |
| FCF Per Share | -0.06 |
Margins
Gross margin is 100%, with operating and profit margins of -26.91% and -262.03%.
| Gross Margin | 100% |
| Operating Margin | -26.91% |
| Pretax Margin | -26.91% |
| Profit Margin | -262.03% |
| EBITDA Margin | -2253.38% |
| EBIT Margin | -26.91% |
| FCF Margin | -428.62% |
Dividends & Yields
PBAXW does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -0.36% |
| FCF Yield | -0.59% |
Analyst Forecast
Currently there are no analyst rating for PBAXW.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -147263.78 |
| Piotroski F-Score | 4 |